SLC5A2 and metabolic dysfunction-associated steatotic liver disease: Future research should investigate whether combining SGLT2 inhibitors with other pharmacological agents, such as GLP-1 receptor agonists or PPAR agonists, yields additive benefits in reducing hepatic fat and preventing MASLD progression.